These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 15262456)

  • 1. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.
    Malacco E; Santonastaso M; Varì NA; Gargiulo A; Spagnuolo V; Bertocchi F; Palatini P;
    Clin Ther; 2004 Jun; 26(6):855-65. PubMed ID: 15262456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
    Black HR; Graff A; Shute D; Stoltz R; Ruff D; Levine J; Shi Y; Mallows S
    J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study.
    Malacco E; Varì N; Capuano V; Spagnuolo V; Borgnino C; Palatini P;
    Clin Ther; 2003 Nov; 25(11):2765-80. PubMed ID: 14693303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study.
    Fogari R; Zoppi A; Carretta R; Veglio F; Salvetti A;
    J Hypertens; 2002 May; 20(5):1007-14. PubMed ID: 12011663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
    Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
    Everett BM; Glynn RJ; Danielson E; Ridker PM;
    Clin Ther; 2008 Apr; 30(4):661-72. PubMed ID: 18498915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial.
    Pool JL; Glazer R; Crikelair N; Levy D
    Clin Drug Investig; 2009; 29(12):791-802. PubMed ID: 19888785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
    Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
    Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide.
    Benz J; Oshrain C; Henry D; Avery C; Chiang YT; Gatlin M
    J Clin Pharmacol; 1997 Feb; 37(2):101-7. PubMed ID: 9055135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achieving BP goals with valsartan and HCTZ alone and in combination: pooled analysis of two randomized, double-blind, placebo-controlled studies.
    Nash DT; Crikelair N; Zappe D
    Curr Med Res Opin; 2008 Sep; 24(9):2617-26. PubMed ID: 18687165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension.
    Bremner AD; Baur M; Oddou-Stock P; Bodin F
    Clin Exp Hypertens; 1997 Nov; 19(8):1263-85. PubMed ID: 9385475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial.
    White WB; Calhoun DA; Samuel R; Taylor AA; Zappe DH; Purkayastha D
    J Clin Hypertens (Greenwich); 2008 Jun; 10(6):450-8. PubMed ID: 18550935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
    Elliott WJ; Calhoun DA; DeLucca PT; Gazdick LP; Kerns DE; Zeldin RK
    Clin Ther; 2001 Aug; 23(8):1166-79. PubMed ID: 11558856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
    Pool JL; Glazer R; Weinberger M; Alvarado R; Huang J; Graff A
    Clin Ther; 2007 Jan; 29(1):61-73. PubMed ID: 17379047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.